The Carmat Aeson Total Artificial Heart: A Critical Analysis of a Medical Milestone

The Carmat Aeson Total Artificial Heart: A Critical Analysis of a Medical Milestone

Executive Summary: Separating Hype from Reality

The Carmat Aeson Total Artificial Heart (TAH) is an authentic and operational medical device, representing a significant and innovative advancement in the field of mechanical circulatory support. However, the promotional description provided presents a heavily romanticized and fundamentally misleading narrative. This portrayal omits critical limitations, substantial risks, the device's true clinical purpose, and the precarious corporate reality of its manufacturer. A comprehensive analysis of the available technical, clinical, and corporate data reveals a technology that is far more complex and compromised than the utopian vision suggests.

The core findings of this report can be synthesized as follows:

Purpose versus Promise: The Aeson TAH is not a permanent heart replacement that "frees thousands from transplant waitlists." Its current regulatory approval and clinical application are strictly as a "bridge to transplant" (BTT). It is a temporary, life-sustaining measure for patients with end-stage biventricular heart failure, designed to keep them alive and physiologically stable until a human donor heart becomes available, typically within a 180-day timeframe. It is a tool to survive the wait, not to eliminate it.

Technological Trade-offs: The device's sophisticated design incorporates bioprosthetic materials, pulsatile flow, and an advanced autoregulation system that mimics the natural heart's response to physical activity. These features offer clear physiological advantages and quality-of-life improvements over older technologies. However, this complexity is achieved by embedding all critical electronic components within the implant, creating a system where a single sensor or microprocessor failure may necessitate a high-risk surgery to replace the entire device.

The Tethered Reality: The assertion that patients can "live, move, and breathe freely" with "no hospital hookups" is a gross exaggeration. Recipients are permanently tethered to an external power supply and control unit via a percutaneous driveline—a cable that passes through the skin of the abdomen. This external system, weighing approximately 4 kg, must be carried at all times and presents a constant, lifelong risk of infection at the driveline exit site, profoundly constraining a patient's lifestyle.

Corporate Instability: The developer, French MedTech company Carmat SA, has faced severe financial distress, including filing for insolvency and entering a receivership procedure in mid-2025. This corporate fragility casts a significant shadow over the long-term viability of the technology, raising critical questions about future development, manufacturing, and, most importantly, the ongoing support for the small cohort of patients whose lives depend entirely on the device.

In conclusion, the Aeson TAH is a promising but highly provisional technology. It is a high-stakes, last-resort intervention for the most critically ill heart failure patients. It is far from the simple, "no compromise" solution described, and its reality is defined by a complex interplay of medical benefit, profound lifestyle constraints, inherent clinical risks, and significant corporate uncertainty.

The Aeson Prosthesis: An In-Depth Technological Assessment

To accurately evaluate the Carmat Aeson TAH, it is essential to deconstruct its design, materials, and operational principles. The device is a product of decades of research, combining biological materials with aerospace-grade engineering to create a prosthesis that aims to mimic the native heart's function more closely than any predecessor.

Anatomy of a Bioprosthetic Heart: Materials and Mechanism

At its core, the Aeson TAH is an orthotopic, biventricular, pulsatile prosthesis intended to fully replace the patient's native ventricles. The device is actuated by an internal electro-hydraulic system. Two miniaturized rotary pumps shuttle a viscous fluid back and forth, which in turn actuates flexible membranes that separate the hydraulic fluid from the blood. This mechanism produces a pulsatile blood flow that mimics the natural systolic and diastolic phases of a heartbeat. This design stands in stark contrast to the older, established SynCardia TAH, which relies on an external, noisy pneumatic driver to pump air into the device. The Aeson's silent internal operation represents a major improvement in patient quality of life.

The materials used in its construction are a key element of its design philosophy. The main structural housing is fabricated from PEEK (polyether ether ketone), a biocompatible and highly durable engineering thermoplastic capable of withstanding the mechanical stresses of continuous operation. However, the most critical innovation lies in the surfaces that come into contact with blood. Pioneered by the project's visionary, French cardiac surgeon Professor Alain Carpentier, these surfaces—including the large membranes that drive blood flow and the four integrated heart valves—are made from chemically treated bovine pericardial tissue (tissue from the sac surrounding a cow's heart). This bioprosthetic design is intended to enhance hemocompatibility, making the surfaces less likely to provoke the formation of blood clots (thrombosis). This, in turn, may reduce the risk of stroke and lessen the need for the aggressive anticoagulation therapy required by devices with purely mechanical surfaces.

The Principle of Autoregulation: A "Smart" Heart

Perhaps the most defining feature of the Aeson TAH is its capacity for self-regulation, a feature that allows it to function as a "smart" heart. Unlike previous generations of artificial hearts that operate at a fixed rate, Aeson is designed to adapt its output to the patient's physiological needs in real time. This is achieved through a sophisticated array of embedded sensors. Pressure sensors within each ventricle monitor preload (the pressure of blood returning to the heart) and afterload (the resistance the heart must pump against), while ultrasound transducers measure the position of the pumping membranes.

This continuous stream of data is fed into an onboard microprocessor that runs a proprietary algorithm. This algorithm automatically adjusts the device's beat rate, which can range from 35 to 150 beats per minute, and its stroke volume to produce a cardiac output of between 2 and 9 liters per minute. This system is designed to emulate a fundamental principle of cardiac physiology known as Starling's law, where the heart naturally increases its output in response to increased venous return. In practical terms, this means the Aeson device can automatically increase blood flow when a patient is physically active, such as when climbing stairs, and decrease it during periods of rest.

The efficacy of this autoregulation system has been documented in clinical settings. An analysis of data from the first 10 patients in a European trial, covering a cumulative 1,842 days of support, demonstrated that the auto-mode was highly effective and required minimal manual adjustments by clinicians after the initial postoperative stabilization period. This adaptive capability is a significant leap forward, aiming to provide patients with a more physiologic response and a better quality of life.

The Tethered Life: Power, Portability, and the Percutaneous Driveline

The advanced internal technology of the Aeson TAH is entirely dependent on an external power source. The device is not a self-contained unit. Power and data are transmitted through a percutaneous driveline, a flexible cable approximately 8 mm in diameter that exits the patient's body through the skin of the abdomen. This driveline is a permanent and life-critical connection.

It connects the implanted heart to an external system that the patient must wear continuously. This system is housed in a carry bag and consists of a controller, which manages the device's operation, and a set of four lithium-ion batteries. The entire external pack weighs around 4 kg and provides approximately four hours of autonomy before the batteries must be swapped for a freshly charged set. While this system does grant the patient significant mobility and allows for discharge from the hospital to lead a "near-normal life," it is a profound and permanent compromise. The concept of being "free" is relative; the patient is forever tethered to this external equipment. Furthermore, the driveline exit site represents a permanent breach of the skin's protective barrier, creating a constant potential portal for infection that requires meticulous daily care.

The design philosophy behind the Aeson TAH represents a fundamental engineering trade-off. The project's goal was to achieve a high degree of biomimicry—replicating the pulsatile, adaptive, and hemocompatible nature of the biological heart. To realize this vision, Carmat's engineers integrated a host of complex, miniaturized components directly into the implanted device: the pumps, the motors, the pressure sensors, the ultrasound transducers, and the microprocessors that control them all. This integration is what enables the device's signature features of silent operation and autoregulation.

However, this "all-in-one" architecture introduces a critical vulnerability. In contrast, the older SynCardia TAH externalizes its primary drivers; the large pneumatic console can be serviced, repaired, or replaced without operating on the patient. For the Aeson TAH, a failure of any single embedded electronic component—a sensor drifting out of calibration or a microprocessor malfunctioning—cannot be repaired. The only solution is the surgical explantation and replacement of the entire device, a formidable and high-risk procedure. In prioritizing physiological performance, Carmat has sacrificed modularity and reparability. This decision makes the device's long-term mechanical and electronic reliability not just a performance metric, but a matter of life and death.

The Clinical Evidence: Patient Outcomes, Trials, and Tribulations

The true measure of any medical device is its performance in human patients. The Carmat Aeson TAH has undergone a series of clinical trials to assess its safety and efficacy, providing a growing body of evidence that helps to define its role, its benefits, and its limitations in the treatment of advanced heart failure.

Indication and Application: A Bridge, Not a Destination

The regulatory approvals and clinical trial protocols for the Aeson TAH are clear and consistent on one critical point: the device is indicated as a bridge to transplant. Its purpose is to provide temporary mechanical circulatory support for patients suffering from end-stage biventricular heart failure (defined as INTERMACS profiles 1-4) who are awaiting a heart transplant. The indication further specifies that these are patients for whom maximal medical therapy and other support devices, such as a Left Ventricular Assist Device (LVAD), are no longer viable options. The device is intended for patients who are likely to undergo transplantation within 180 days of implantation.

This context is crucial. The Aeson TAH is not designed or approved to be a permanent replacement for the human heart, often referred to as "destination therapy." While this remains the company's long-term ambition, the current clinical reality is one of temporary support. The longest documented period a patient has been supported by an Aeson device is 25 months. Early in the device's history, the first patient implanted in December 2013 survived for 74 days, which at the time exceeded the trial's 30-day success benchmark. This underscores that the device's role is to stabilize critically ill patients, allowing them to regain strength and survive the often-lengthy wait for a suitable donor organ.

A Synthesis of Clinical Trial Data

Several key clinical studies have provided data on the Aeson TAH's performance:

The PIVOTAL Study: This was the key study that led to the device's initial CE marking in Europe. In a cohort of 15 patients, the study demonstrated a 73% success rate at six months, with success defined as either survival with the device or having received a successful heart transplant within that period. The study also highlighted a safety profile that appeared favorable when compared to historical data for the SynCardia TAH. At six months, the Aeson cohort had experienced no strokes and no driveline infections, which contrasted sharply with reported rates for SynCardia of 23% for stroke and 41% for major bleeding.

The EFICAS Study: To gather more robust data for reimbursement purposes, particularly in France, Carmat initiated this prospective, multicenter study designed to enroll 52 patients. The primary endpoint is survival for 180 days post-implantation without a disabling stroke, or a successful heart transplant within that same 180-day window. Interim results have been encouraging; among the first eight patients who reached the six-month follow-up point, the success rate was 75%, a figure that exceeded the study's predefined expectations.

Cardiogenic Shock Cohort: A retrospective analysis published in the JACC: Heart Failure journal provided compelling evidence of the device's utility in the most desperate clinical scenarios. The study examined 10 patients in refractory cardiogenic shock who were so ill they first had to be stabilized on temporary extracorporeal life support (ECLS or ECMO). These patients were transitioned to the Aeson TAH and showed a remarkable 90% survival rate at six months. At that point, five of the patients had been successfully transplanted, and four were still alive and supported by the device. This study powerfully illustrates the device's role as a salvage therapy for patients who would otherwise have an extremely high short-term mortality risk.

U.S. Early Feasibility Study (EFS): The path to approval in the United States is significantly more rigorous than in Europe. Carmat has received approval from the U.S. Food & Drug Administration (FDA) to conduct an EFS. This is a small-scale trial, initially planned for 10 patients across several experienced U.S. centers like VCU Medical Center, designed primarily to evaluate the device's safety in the American clinical environment. This study represents the very first step on a long and costly regulatory journey toward potential U.S. market approval.

The Safety Profile and Known Complications

While Carmat's clinical data suggests a favorable safety profile relative to its main competitor, the implantation of any TAH is an inherently high-risk procedure performed on the most fragile of patients. The general categories of adverse events associated with TAHs include major bleeding, neurologic events such as stroke, device malfunction, and life-threatening infections. Case reports involving the Aeson device often describe its use in patients with exceptionally complex conditions, such as those with a massive ventricular septal rupture following a heart attack, who had already developed bleeding and infectious complications from prior ECMO support. While the Aeson proved life-saving in these instances, they highlight the "last resort" nature of the therapy.

A significant limitation that impacts the device's safety and applicability is its physical size. The Aeson TAH has a large displacement volume of at least 750 ml, which requires a capacious thoracic cavity to accommodate it. This effectively excludes a large portion of the potential patient population. Virtual fitting studies based on CT scans have shown that while the device would fit in an estimated 86% of male patients, it would only be suitable for approximately 14% of female patients, as well as being too large for many smaller-statured men. This size constraint is a major barrier to wider adoption and necessitates the development of a miniaturized version.

The clinical data reveals a critical paradox that must be understood to properly contextualize the Aeson TAH's performance. The user's provided text implies a broadly applicable, low-risk solution, but the reality is the opposite. The patient population eligible for this device consists of the "sickest of the sick": individuals in end-stage biventricular failure, often in cardiogenic shock, for whom all other medical and device therapies have failed or are contraindicated. These patients face a near-certain risk of death in the short term. Therefore, when a clinical trial reports a 75% or 90% survival rate at six months, this figure must be measured against a grim baseline where survival would have been close to zero. The device's success is not a reflection of a low-risk procedure but rather a testament to its efficacy as a salvage therapy in the most extreme circumstances. This paradox is central to debunking the notion of a simple, compromise-free solution; the Aeson TAH's value is most profoundly demonstrated in the very patient group that highlights its nature as a high-stakes, last-resort intervention.

The Broader Context: Regulatory, Competitive, and Corporate Realities

The viability of a medical device like the Aeson TAH is determined not only by its technological sophistication and clinical performance but also by its position within the broader regulatory, competitive, and corporate landscape. These external factors are critical to understanding its real-world potential and limitations.

The Regulatory Gauntlet: Europe vs. The U.S.

Carmat has navigated two very different regulatory environments with varying degrees of success.

Europe: The Aeson TAH has achieved CE marking, which permits its commercial sale within the European Union and other countries that recognize this standard. Initially approved under the Medical Device Directive (MDD), the device received a crucial updated CE mark in July 2025 that complies with the new, more stringent Medical Devices Regulation (MDR). The MDR requires a higher level of clinical evidence and more robust post-market surveillance, making this certification a significant validation of the device's quality and safety data.

United States: The pathway to the U.S. market is substantially longer and more demanding. As of late 2025, the Aeson TAH is not commercially available in the U.S. and is considered an investigational device. The company has only gained FDA approval for an Early Feasibility Study (EFS) with a small patient cohort. Full Pre-Market Approval (PMA) from the FDA, which would allow for commercialization, is a multi-year, multi-phase process. Carmat has stated that it anticipates achieving PMA in 2027 at the earliest, a timeline that is contingent on successful trial outcomes and the company's ability to fund these extensive studies.

The Competitive Landscape: Aeson vs. The Alternatives

The Aeson TAH does not exist in a vacuum. It is an option within a spectrum of treatments for advanced heart failure. Its primary competitors are the incumbent SynCardia TAH and the more widely used Left Ventricular Assist Devices (LVADs).

vs. SynCardia TAH: The SynCardia device is Aeson's only direct competitor in the TAH market. While technologically less advanced—relying on external pneumatic drivers, having purely mechanical blood-contacting surfaces, and lacking autoregulation—SynCardia has the significant advantage of a much longer history and a larger body of clinical experience, with over 1,300 implants worldwide and full FDA approval as a bridge to transplant.

vs. LVADs: LVADs are surgically implanted pumps that support the heart's main pumping chamber, the left ventricle, while leaving the native heart in place. They are a far more common therapy than TAHs and are used for patients whose right ventricle function is still adequate. A TAH like Aeson is reserved for the smaller, sicker subset of patients who have progressed to biventricular failure, where both ventricles have failed and require full replacement.

The following table provides a comparative analysis of these mechanical circulatory support options.

Feature

Carmat Aeson TAH

SynCardia TAH

Left Ventricular Assist Device (LVAD)

Indication

Biventricular Failure (Bridge to Transplant)

Biventricular Failure (Bridge to Transplant)

Left Ventricular Failure (Bridge to Transplant or Destination Therapy)

Actuation

Internal Electro-hydraulic

External Pneumatic (Air-driven)

Internal Continuous-Flow Rotary Pump

Blood Surfaces

Bioprosthetic (Bovine Tissue)

Mechanical (Polyurethane)

Mechanical (Metals, Polymers)

Autoregulation

Yes (Sensor-based, adaptive output)

No (Fixed beat rate)

No (Fixed pump speed, adjusted by clinician)

Noise

Silent

Audible "clicking" from driver

Quiet hum

Regulatory (US)

EFS only (Investigational)

FDA Approved (PMA)

FDA Approved (PMA)

Regulatory (EU)

CE Mark (MDR)

CE Mark

CE Mark

Key Limitations

Size constraints, corporate viability, limited long-term data

Noise, fixed output, need for high anticoagulation

Only supports one ventricle, risk of right heart failure

Corporate Health and Future Viability: The Elephant in the Room

The most significant threat to the Aeson TAH's future may not be technological or clinical, but financial. Carmat SA has experienced profound and persistent financial difficulties. In mid-2025, the company's situation became critical, leading it to file for insolvency and be placed in a receivership procedure by French courts due to an acute lack of funds. A press release from June 2025 starkly noted that the company's existing cash runway was limited to the middle of that month.

While the company has continued to operate under the protection of the receivership—focusing its limited resources on essential activities like supporting existing patients and pursuing regulatory milestones—this financial instability is a grave concern. During this period, the company was forced to temporarily halt new commercial implants. The long-term survival of Carmat SA is far from guaranteed and will depend on its ability to secure substantial new funding and successfully exit the receivership procedure.

This corporate fragility creates a unique and deeply concerning dynamic for patients. A recipient of an Aeson TAH is completely dependent on the device for every single heartbeat. This dependence extends beyond the physical implant to the entire support ecosystem that Carmat provides: the proprietary software used by clinicians to monitor the device, the supply chain for external components like batteries and controllers, and the specialized training required for surgical and post-operative teams. The documented insolvency of Carmat means that the very entity responsible for this entire life-sustaining ecosystem is at risk of collapse.

This situation establishes an unprecedented symbiotic risk, where a patient's biological survival becomes inextricably linked to the financial solvency and corporate health of a single company. Should Carmat cease to exist, critical questions arise with no clear answers. Who would provide the technical support for the 50-plus patients already implanted with the device? Who would manufacture replacement external components? Who would train new medical teams if a patient needs to be transferred to a different hospital? This profound dependency on a financially unstable company represents the single greatest "compromise" a patient must accept—a risk entirely absent from the romanticized marketing narrative.

Verdict: Deconstructing the Claims

This section directly evaluates the claims made in the user's provided text against the body of evidence presented in this report.

Claim: "An artificial heart that beats endlessly." Verdict: False. This is hyperbole. The device has a finite, though yet to be fully determined, mechanical lifespan. Its current clinical application is explicitly temporary, serving as a bridge to transplant for a period of months, not indefinitely. The longest reported use in a patient is 25 months, far from "endless". The ultimate goal for future generations of such devices is a lifespan of 10-20 years, but this is a distant aspiration, not a current reality.

Claim: "Could soon free thousands from transplant waitlists." Verdict: Misleading. The device does not "free" patients from the transplant waitlist; it is a tool designed to help them survive while on the waitlist. Its entire purpose in its current indication is to get a patient to a successful transplant. It adds a new step to the treatment pathway for the sickest patients; it does not eliminate the need for a donor organ.

Claim: "No hospital hookups." Verdict: Highly Misleading. While the Aeson TAH allows a patient to be discharged from the hospital, they are permanently "hooked up" to an external 4 kg equipment pack via a driveline that penetrates their skin. This is a constant, life-sustaining connection that must be managed 24 hours a day. The claim is only true in the narrowest sense that the patient is not confined to a hospital bed.

Claim: "Live, move, and breathe freely." Verdict: Exaggerated. Patients can indeed regain a remarkable degree of mobility and quality of life compared to their pre-operative state of being critically ill and often bedridden. However, their freedom is significantly constrained by the need to carry the external equipment, the constant management of battery life, and the meticulous care required to prevent a potentially fatal driveline infection.

Claim: "Sustain life for months, even years, without complications." Verdict: Partially True, but Lacks Context. The device has proven it can sustain life for months and, in at least one case, for over two years. However, the notion of doing so "without complications" is a dangerous oversimplification. The implantation is a major surgery on an extremely high-risk patient, and the potential for severe adverse events—including bleeding, stroke, infection, and device malfunction—is an ever-present reality for any TAH recipient. The relatively low complication rates seen in trials are a testament to the device's design, but they do not eliminate risk.

Claim: "This isn’t just a device. It’s a second chance at life — no waiting, no compromise." Verdict: False. The Aeson TAH unequivocally offers a second chance at life for patients who have no other options. However, the claim of "no compromise" is the most inaccurate and misleading statement in the entire description. The therapy involves immense and life-altering compromises: undergoing a massive surgical procedure; living with a permanent driveline through the abdomen; being perpetually dependent on external, battery-powered equipment; facing the lifelong risk of severe complications; and, most critically, entrusting one's life to a device manufactured by a company with a documented history of financial insolvency.

Conclusion: A Promising but Provisional Milestone

The Carmat Aeson Total Artificial Heart is not a work of fiction, but a tangible and laudable feat of biomedical engineering. Its development represents a genuine step forward in the decades-long quest to create a functional replacement for the human heart. The innovations in biocompatible materials, silent electro-hydraulic actuation, and sensor-driven autoregulation are real and offer significant clinical benefits over previous technologies.

However, the device must be understood for what it is today, not what it may one day become. It is not a mainstream, low-risk alternative to transplantation. It is an extreme intervention for a small and desperate subset of patients with end-stage biventricular heart failure—a last resort when all other options have been exhausted. Its clinical successes, while impressive, must be interpreted within the context of this critically ill patient population, for whom the alternative is often imminent death. The Aeson TAH is a high-risk solution for a high-risk problem.

The future of this technology, and its potential evolution from a temporary bridge to a permanent solution, hinges on overcoming three formidable challenges:

Demonstrating Long-Term Durability: The device's reliability must be proven over a span of many years, not just the months required for its current bridge-to-transplant application. This will require extensive bench testing and long-term data from implanted patients.

Technological Refinement and Miniaturization: To become a more broadly applicable therapy, a smaller version of the device must be developed to fit a wider range of patients, particularly women. The ultimate goal for any permanent artificial heart is the development of a fully implantable system with a wireless, transcutaneous energy transfer system, thereby eliminating the problematic percutaneous driveline.

Achieving Corporate Survival: Most immediately, Carmat SA must secure its long-term financial stability. Without a viable and solvent company to manufacture the device, train medical teams, and provide ongoing support to patients, the technology's potential cannot be realized.

The Aeson TAH is a crucial and inspiring milestone on the long and arduous road toward a true, permanent artificial heart. It provides profound hope and a tangible chance at life where none existed before. It is, however, not the final destination. It is a work in progress, a powerful testament to both the incredible potential of modern medical technology and the immense scientific, clinical, and financial challenges that remain.

Works cited

1. Our Product - Carmat, https://www.carmatsa.com/en/our_product/ 2. First Clinical Experience With the Pressure Sensor–Based ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC8478302/ 3. Présentation PowerPoint - Carmat, https://www.carmatsa.com/carmat-content/uploads/2022/01/carmat_presentation_31january2022_en.pdf 4. CARMAT total artificial heart | European Journal of Cardio-Thoracic ..., https://academic.oup.com/ejcts/article/46/6/933/2755263 5. Could Carmat's Artificial Heart Be a Game-Changer? - MedicalExpo e-Magazine, https://emag.medicalexpo.com/could-carmats-artificial-heart-be-a-game-changer/ 6. Artificial heart developer gains key approval as money troubles ..., https://cardiovascularbusiness.com/topics/clinical/cardiac-surgery/artificial-heart-developer-gains-key-approval-money-troubles-continue 7. Home - Carmat :Carmat, https://www.carmatsa.com/en/ 8. A New Hope for Heart Patients: Aeson Artificial Heart Implanted at Sheba Medical Center, https://www.shebaonline.org/carmat-artificial-heart-transplant-at-sheba/ 9. Carmat notches a win as artificial heart patient returns home | Fierce Biotech, https://www.fiercebiotech.com/medical-devices/carmat-notches-a-win-as-artificial-heart-patient-returns-home 10. Nursing Management Strategies for a Patient With an Aeson CARMAT® Total Artificial Heart: a Case Report - FUPRESS, https://riviste.fupress.net/index.php/if/article/download/3501/2256/23262 11. The First Person to Receive a Carmat Artificial Heart is Dead After 75 Days - Time Magazine, https://time.com/12050/worlds-first-artificial-heart-receiver-dies-after-75-days/ 12. VCU Medical Center leading clinical trial of advanced artificial heart, https://www.vcuhealth.org/pauley-heart-center/the-beat/all-issues/autumn-2020/vcu-medical-center-leading-clinical-trial-of-advanced-artificial-heart/ 13. CARMAT continues to build on its momentum in the EFICAS study and reiterates confidence in its 2024 outlook, https://www.carmatsa.com/en/press-release/carmat-continues-to-build-on-its-momentum-in-the-eficas-study-and-reiterates-confidence-in-its-2024-outlook/ 14. About Carmat, https://www.carmatsa.com/en/about-carmat/ 15. CARMAT completes enrolment in the EFICAS clinical study and receives approval from French authorities for 21 additional Aeson® implants, while awaiting potential reimbursement of the device in France, https://www.carmatsa.com/en/news/carmat-completes-enrolment-in-the-eficas-clinical-study-and-receives-approval-from-french-authorities-for-21-additional-aeson-implants-while-awaiting-potential-reimbursement-of-the-device-in-fr/ 16. CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson® Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support - Business Wire, https://www.businesswire.com/news/home/20250403031108/en/CARMAT---Publication-in-the-JACC1-Heart-Failure-of-the-Initial-Clinical-Experience-with-Aeson-Total-Artificial-Heart-in-Cardiogenic-Shock-Patients-Initially-Placed-on-Extracorporeal-Life-Support 17. Publication in the JACC: Heart Failure of the initial clinical experience with Aeson® total artificial heart in cardiogenic shock patients initially placed on extracorporeal life support - Carmat, https://www.carmatsa.com/en/press-release/publication-in-the-jacc-heart-failure-of-the-initial-clinical-experience-with-aeson-total-artificial-heart-in-cardiogenic-shock-patients-initially-placed-on-extracorporeal-life-support/ 18. Adverse Events under Temporary Total Artificial Heart Support (N = 217 Patients) - ResearchGate, https://www.researchgate.net/figure/Adverse-Events-under-Temporary-Total-Artificial-Heart-Support-N-217-Patients_tbl3_350224362 19. the first experience with the Aeson bioprosthetic total artificial heart as a bridge to transplantation in a case of post-infarction ventricular septal rupture - PubMed, https://pubmed.ncbi.nlm.nih.gov/37840948/ 20. the first experience with the Aeson bioprosthetic total artificial heart as a bridge to transplantation in a case of post-infarction ventricular septal rupture - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC10570445/ 21. Case report—CARMAT: the first experience with the Aeson bioprosthetic total artificial heart as a bridge to transplantation in a case of post-infarction ventricular septal rupture - Frontiers, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1211365/full 22. CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union - Business Wire, https://www.businesswire.com/news/home/20250601360042/en/CARMAT-Announces-the-First-Commercial-Implants-of-Its-Aeson-Artificial-Heart-Outside-the-European-Union 23. Present and future perspectives on total artificial hearts - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC4250545/ 24. Total artificial hearts: Exploring the future of heart transplant technology with a renowned surgeon - Cardiovascular Business, https://cardiovascularbusiness.com/topics/clinical/cardiac-surgery/total-artificial-hearts-exploring-future-heart-transplant-technology 25. Total Artificial Heart | NYU Langone Health Physician Focus, https://physicianfocus.nyulangone.org/the-future-of-the-total-artificial-heart/